AVE Science & Technology Co

AVE Science & Technology Co EBIT Growth

The Year-over-Year EBIT Growth of AVE Science & Technology Co (688067.SS) as of Nov 16, 2026 is 27.65 %. In the previous year, Year-over-Year EBIT Growth was 5.50 % — a change of 402.75% (higher).

EBIT Growth

27.65 %

YoY

402.75%

Last updated:

Year-over-Year EBIT Growth of AVE Science & Technology Co is 2025 27.65 % . Year-over-Year EBIT Growth of AVE Science & Technology Co was 2024 5.50 % . It decreases by 402.75% higher compared to the previous year.

The AVE Science & Technology Co EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2018
-2.02 CNY
Jan 1, 2019
90.46 CNY
Jan 1, 2020
-40.08 CNY
Jan 1, 2021
-0.71 CNY
Jan 1, 2022
-45.88 CNY
Jan 1, 2023
20.89 CNY
Jan 1, 2024
5.50 CNY
Jan 1, 2025
27.65 CNY
The AVE Science & Technology Co EBIT Growth history
YEAREBIT GrowthYoY
27.65 %+402.75%
5.50 %-73.67%
20.89 %-145.52%
-45.88 %+6,403.52%
-0.71 %-98.24%
-40.08 %-144.31%
90.46 %-4,589.11%
-2.02 %-105.06%
39.84 %-16.25%
47.58 %+1.50%
46.87 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AVE Science & Technology Co Stock analysis

What does AVE Science & Technology Co do? AVE Science & Technology Co., Ltd. generates revenue through the research, development, production, sale, and service of clinical testing and analysis instruments. Its main products include urine formed component analyzer, urine dry chemistry analyzer, urine full item automatic analyzer, automatic stool analyzer, automatic body fluid analyzer, reproductive tract secretion analyzer, and special supporting in vitro diagnostic reagents and medical consumables. These products are primarily sold to inspection departments within medical and health institutions in both domestic and overseas markets. The company serves healthcare facilities that require diagnostic equipment for laboratory testing and patient care. The firm's product portfolio targets healthcare institutions seeking advanced diagnostic tools for efficient clinical analysis. By focusing on specialized instruments like urine and stool analyzers, AVE Science & Technology addresses specific needs in medical testing departments. The company's domestic and international distribution channels ensure broad market access for its diagnostic solutions. AVE Science & Technology's revenue streams are derived from the sale of its comprehensive range of clinical testing instruments and related consumables. The company's domestic market presence and overseas sales contribute to its overall business performance. Its products support routine diagnostic procedures across various healthcare settings, driving consistent demand for its equipment and reagents. AVE Science & Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AVE Science & Technology Co stock

Year-over-Year EBIT Growth of AVE Science & Technology Co is 27.65 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth AVE Science & Technology Co since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's AVE Science & Technology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — AVE Science & Technology Co

All Key Metrics — AVE Science & Technology Co